EVER Pharma Launches a Digital Training App for the D-mine® Pump
12.7.2022 15:00:00 EEST | Business Wire | Press release
After successfully launching the D-mine ® Pump, an infusion device designed to provide precise continuous subcutaneous drug delivery for Parkinson´s patients, EVER Pharma developed an App to support the training needs of Healthcare Professionals and caregivers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220712005103/en/
The digital Training App for the D-mine® Pump supporting the training needs (Graphic: Business Wire)
EVER Pharma, a specialist in neurological diseases, offers a complete therapy package for Parkinson’s disease with D-mine® Pump, D-mine ® Pen and Dacepton® (Dopaceptin®, Apomorphine hydrochloride) and with its new D-mine® Pump TRAINING APP a simulation tool to support the training and the programing of the D-mine ® Pump.
The App can be easily downloaded and installed onto Android or iOS devices by Healthcare Professionals or caregivers who are working with the D-mine ® Pump and managing the therapy of Parkinson´s patients with infusion therapy.
“With the development of the TRAINING APP for the D-mine ® Pump in Parkinson's therapy, we now have an empowering and interactive tool to support the training of the Healthcare Professionals and caregivers on how to use and program the infusion pump device. The App is an intuitive, easy-to-use simulator and enables training any time everywhere”, explains Georges Kahwati, General Manager at EVER Pharma GmbH.
For more information please visit www.d-minecare.com.
About EVER Pharma GmbH
EVER Pharma is a fully integrated specialty pharmaceuticals company focused on the research, development, production and commercialization of products in the areas of neurology, critical care, anesthesia and oncology.
From its global headquarters in Austria, Ever Pharma provides innovative therapies and value-added formulations aimed at enhancing patient and healthcare professional’s lives through improved safety and convenience.
The products are developed and manufactured at EU GMP certified facilities in Austria and Germany. The technical operations are highly specialized in the production of complex injectables including high potency substances, crystal suspensions, oily solutions and controlled substances in vials, pre-filled syringes, cartridges, ampoules and implants. EVER markets its products in more than 80 countries around the world through 30 international affiliated companies and strategic partners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220712005103/en/
Contact information
Contact Press
Marie-Kristin Schöppl
International Marketing Manager
Phone: +43 7665 20555 530
E-Mail: marie-kristin.schoeppl@everpharma.com
www.everpharma.com
www.d-minecare.com
Contact Partner/Investor Relations
Dominic Benning
Head of Dopaminergic Therapy
Phone: +43 7665 20555 861
E-Mail: dominic.benning@everpharma.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fourthline Trust Services Granted Status as Qualified Trust Service Provider in the EU24.8.2026 16:13:00 EEST | Press release
Fourthline Trust Services AB, a subsidiary of Fourthline, has been granted qualified status under the EU's eIDAS Regulation (910/2014)¹ and is now listed on the EU Trusted List as a Qualified Trust Service Provider (QTSP). Supervised by the Swedish Post and Telecom Authority (Post- och telestyrelsen, PTS), Fourthline Trust Services AB issues qualified certificates for electronic signatures. Fourthline, is the leading European provider of AI-powered identity verification (IDV) and compliance solutions. This milestone allows Fourthline full control over the entire digital trust value chain from identity verification to qualified electronic signature (QES) issuance. Ralph Post, Fourthline Trust Services AB Board Member: "By building our QTSP infrastructure similar to our sovereign AI-powered platform that drives our industry-leading identity verification, we're able to offer unprecedented security, performance, and innovation. Organisations can now accelerate their digital transformation
SLB Launches ExaCT Electrical Downhole CT Control System24.8.2026 14:02:00 EEST | Press release
SLB (NYSE: SLB) today launched the ExaCT™ electrical downhole coiled tubing (CT) control system, an advanced intervention platform that introduces real-time electrical control to coiled tubing operations. By replacing pressure-dependent hydraulic actuation with electrical communication, power delivery and telemetry, the ExaCT system gives operators greater visibility, precision and control, helping improve intervention execution and reservoir access. The ExaCT system combines electrical power, telemetry and downhole measurements to enable communication with, actuation of and verification of downhole tools throughout an intervention. Continuous communication across the toolstring enables on-demand tool actuation across a wide range of intervention applications, including extended-reach and multilateral wells. The increased precision and control provided by the system help operators optimize reservoir access, improve production performance and maximize recovery. "Operators are asking int
Wolters Kluwer Transforms Trusted Legal Content Into Structured, AI-Ready Intelligence That Powers the Next Wave of Legal AI24.8.2026 14:01:00 EEST | Press release
Wolters KluwerLegal & Regulatory today announced the next evolution of Libra by Wolters Kluwer, its all-in-one Legal AI Workspace. By transforming authoritative legal sources, expert commentaries, and practical guidance into structured legal intelligence, Wolters Kluwer is making the relationships across the full breadth of its expert legal sources more explicit. This will enable deeper contextual research, more comprehensible answers, and workflow-ready results across legal work. Following the integration of Wolters Kluwer content into the Libra AI workspace in the first half of 2026, laws, rulings, expert commentaries, and practical guidance will now be linked to one another and to the matter at hand, creating a connected knowledge graph of expert-curated and authoredlegal knowledge that AI can reason over. For customers, this means research that surfaces the right authority faster, answers with even clearer reasoning and sources, drafting guided by matter-specific context, and great
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S
European Commission Approves DAYBU ® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 10:01:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom